Literature DB >> 18819161

Intravascular large B-cell lymphoma with FDG accumulation in the lung lacking CT/(67)gallium scintigraphy abnormality.

Akira Kitanaka1, Yoshitsugu Kubota, Osamu Imataki, Hiroaki Ohnishi, Tetsuya Fukumoto, Kazutaka Kurokohchi, Terukazu Tanaka.   

Abstract

Intravascular large B-cell lymphoma (IVLBCL) is a rare lymphoma characterized by the presence of large tumour cells within the blood vessels. It has been considered that IVLBCL is a highly malignant disease with poor prognosis. However, it has been shown that a therapeutic effect resembling that of conventional B-cell lymphomas may be obtained with the application of systemic chemotherapy at the early stage of this disease. Although involvement in the lung is often detected at autopsy, early diagnosis is quite difficult. In this report, we present a case of IVLBCL with pulmonary involvement where 18-fluoro-deoxyglucose positron emission tomography (FDG-PET) was useful in the early diagnosis. Neither computed tomography (CT) nor (67)gallium scintigraphy could reveal the presence of disease in the lung. Histological evidence of IVLBCL was obtained by TBLB after FDG uptake in the lung was confirmed by FDG-PET. The patient exhibited a good response to the subsequent combination chemotherapy. We propose that FDG-PET is a powerful tool for the early diagnosis of IVLBCL with pulmonary involvement, if the possibility of this disease presents in the patient with respiratory symptoms without abnormal findings by CT and (67)gallium scintigraphy. Copyright 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18819161     DOI: 10.1002/hon.876

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  8 in total

1.  18F-FDG PET/CT in a case of intravascular large B-cell lymphoma.

Authors:  Yasemin Sanli; Cuneyt Turkmen; Bülent Saka; Isin Kilicaslan; Oner Dogan; Nilgun Erten; Isik Adalet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-06       Impact factor: 9.236

2.  Lung intravascular large B-cell lymphoma with ground glass opacities on chest computed tomography: a case report.

Authors:  Desheng Xiao; Chunyan Fu; Xueying Long; Wei Liu; Chen Chen; Jianhua Zhou; Songqing Fan
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

3.  Pulmonary intravascular lymphoma diagnosed by 18-fluorodeoxyglucose positron emission tomography-guided transbronchial lung biopsy in a man with long-term survival: a case report.

Authors:  Tomiharu Niida; Kikuo Isoda; Koji Miyazaki; Soichiro Kanoh; Hideo Kobayashi; Ayako Kobayashi; Fumihiko Kimura; Katsumi Hayashi; Masatoshi Kusuhara; Fumitaka Ohsuzu
Journal:  J Med Case Rep       Date:  2011-07-07

4.  Diffuse pulmonary uptake on FDG-PET with normal CT diagnosed as intravascular large B-cell lymphoma: a case report and a discussion of the causes of diffuse FDG uptake in the lungs.

Authors:  T Wagner; D Brechemier; E Dugert; S Le Guellec; A Julian; A Hitzel; O Beyne-Rauzy
Journal:  Cancer Imaging       Date:  2012-01-23       Impact factor: 3.909

5.  Early detection of intravascular large B-cell lymphoma by (18)FDG-PET/CT with diffuse FDG uptake in the lung without respiratory symptoms or chest CT abnormalities.

Authors:  Masato Shiiba; Koji Izutsu; Makiko Ishihara
Journal:  Asia Ocean J Nucl Med Biol       Date:  2014

6.  Intravascular large B-cell lymphoma presenting with diffusely increased pulmonary fluorodeoxyglucose uptake without corresponding CT abnormality.

Authors:  Jayden Spencer; Reginald Dusing; Wendell Yap; Jacqueline Hill; Carissa Walter
Journal:  Radiol Case Rep       Date:  2018-11-23

7.  Intravascular B-cell lymphoma: case report of a rare cause of pulmonary arterial hypertension.

Authors:  Michael Share; Gabriel Giannini; Stacey Kim; Siddharth Singh
Journal:  Eur Heart J Case Rep       Date:  2019-02-02

8.  Intravascular large B-cell lymphoma with diffuse FDG uptake in the lung by 18FDG-PET/CT without chest CT findings.

Authors:  Hiroyuki Yamashita; Akitake Suzuki; Yuko Takahashi; Kazuo Kubota; Toshikazu Kano; Akio Mimori
Journal:  Ann Nucl Med       Date:  2012-04-27       Impact factor: 2.668

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.